Latest News

The Wall Street Journal: New omicron-specific COVID booster expected to be approved before trial data is in

0

The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.

The shots, modified to target the latest versions of the omicron variant, won’t have finished testing in humans when the FDA makes its decisions.

Instead, the agency plans to assess the shots using data from other sources such as research in mice, the profiles of the original vaccines and the performance of earlier iterations of boosters targeting older forms of omicron.

“Real world evidence from the current mRNA COVID-19 vaccines, which have been administered to millions of individuals, show us that the vaccines are safe,” FDA Commissioner Robert Califf said in a recent tweet. The FDA pointed to Califf’s tweets when asked for comment.

Clearance of the doses, without data from human testing known as clinical trials, is similar to the approach the FDA takes with flu shots, which are updated annually to keep up with mutating flu viruses.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

Who’s #ThatGirl? What happens when a TikTok trend takes over your life.

Disney’s new pricing magic: More profit from fewer park visitors.

The Fed: What happens next now that Jackson Hole is over? More Fed hawkishness is in the cards

Previous article

Crypto: Bitcoin slips below $20,000 following Powell’s hawkish remarks

Next article

You may also like

Comments

Leave a reply

Your email address will not be published.

More in Latest News